Phase 2 Pancreatic Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with pancreatic ductal adenocarcinoma (a specific type of pancreatic cancer), confirmed by laboratory testing of tissue
• People whose cancer has been staged at certain levels — not too advanced — based on the size of the tumor, whether it has spread to nearby lymph nodes, and confirmation that it has not spread to other parts of the body
• People who have had surgery to remove their pancreatic cancer, where the surgeon was able to remove all visible cancer (with either clear or close margins)
• People who show no signs of remaining disease after surgery, as confirmed by their doctor within 28 days before starting treatment
• People who have had a blood test measuring a cancer marker called CA19-9 within 14 days before starting treatment
• People who are between 6 and 12 weeks past their pancreatic cancer surgery at the time of starting the trial
• People who have recovered fully enough from surgery that their doctor considers them able to receive the three study treatments
• People whose blood counts and organ function (such as liver and kidneys) meet the required health levels
• Female participants of childbearing potential who are willing to avoid pregnancy and egg donation during treatment and for specified periods after their last doses of each study treatment
• Male participants with a partner who could become pregnant who are willing to use specified contraception or remain abstinent during treatment and for specified periods after their last doses of each study treatment, and to avoid donating sperm during this time

Who may not be able to join:

• People who have already received any chemotherapy, radiation, or other cancer treatment before their surgery for pancreatic cancer
• People who are planning to receive additional cancer treatments (such as radiation or chemotherapy) beyond what this trial requires, after finishing the chemotherapy portion of the study
• People who no longer have their spleen, including those who had it removed as part of their pancreatic surgery
• People who already have moderate or severe nerve damage (such as numbness, tingling, or pain in the hands or feet)
• People who have a known complete deficiency of a specific enzyme (DPD) that processes certain chemotherapy drugs, due to inherited genetic changes
• People who have bowel conditions affecting the colon or rectum, or who experienced complications after surgery that cause moderate or severe ongoing diarrhea
• People who are pregnant or breastfeeding
• People who have an active autoimmune disease, a history of autoimmune disease, or a condition that affects the immune system
• People who have taken certain antiviral medications (brivudine, sorivudine, or closely related drugs) within 4 weeks before starting the trial, as these can interfere with how the chemotherapy is processed
• People who are currently taking or planning to take certain medications that strongly affect how the body processes drugs (confirm specific medications with trial site)

Important: Always verify eligibility with the trial site directly before applying.